AC2993 Global Collaboration with Eli Lilly and Company
Goal to maximize potential of AC2993
- Partnership provides global development and marketing reach
- Strong cultural fit between companies
- Governance structure employs consensus decision-making
Financial terms
- $110M received at signing
- $215M in potential development and commercial milestones
- $110M credit facility
- 50/50 profit split in US, Amylin books all US revenues
- 20/80 profit split outside US, Lilly books all OUS revenues